A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. Luminex technology offers a powerful approach for the simultaneous detection of multiple anti-TAA autoantibodies.  (2) Methods: We aimed to utilize Luminex technology to evaluate and optimize a panel of anti-TAAs autoantibodies for detecting prostate cancer (PCa), which included autoantibodies to fourteen TAAs.  A total of 163 serum samples (91 PCa, 72 normal controls) were screened to determine the levels of the autoantibodies using the Luminex assay.  The results obtained from the Luminex assay were consistent with the ELISA findings. 
Luminex
Luminex technology offers a powerful approach for the simultaneous detection of multiple anti-TAA autoantibodies.  (2) Methods: We aimed to utilize Luminex technology to evaluate and optimize a panel of anti-TAAs autoantibodies for detecting prostate cancer (PCa), which included autoantibodies to fourteen TAAs. 
Luminex technology
A total of 163 serum samples (91 PCa, 72 normal controls) were screened to determine the levels of the autoantibodies using the Luminex assay.  The results obtained from the Luminex assay were consistent with the ELISA findings. 
Luminex assay
We further confirmed the performance of the HSP60 autoantibody by using an enzyme-linked immunosorbent assay (ELISA) in a larger sample comprising 200 PCa sera, 20 benign prostatic hyperplasia (BPH) sera, and 137 normal control sera.  The results obtained from the Luminex assay were consistent with the ELISA findings. 
ELISA